Posted by Michael Wonder on 20 Apr 2022
Otsuka announces Health Canada approval of Tavneos (avacopan) for ANCA associated vasculitis
20 April 2022 - Launch is expected in Canada in the fourth quarter of 2022.
Otsuka Canada Pharmaceutical today announced that Health Canada has approved Tavneos (avacopan), an orally administered selective complement 5a receptor inhibitor, for the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis, in combination with standard background therapy including glucocorticoids.
